Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
| Revenue (TTM) | $79.67B |
| Gross Profit (TTM) | $66.44B |
| EBITDA | $41.71B |
| Operating Margin | 54.20% |
| Return on Equity | 102.30% |
| Return on Assets | 20.40% |
| Revenue/Share (TTM) | $89.02 |
| Book Value | $38.00 |
| Price-to-Book | 30.28 |
| Price-to-Sales (TTM) | 13.25 |
| EV/Revenue | 13.45 |
| EV/EBITDA | 25.70 |
| Quarterly Earnings Growth (YoY) | 26.20% |
| Quarterly Revenue Growth (YoY) | 47.70% |
| Shares Outstanding | $891.36M |
| Float | $888.95M |
| % Insiders | 0.16% |
| % Institutions | 85.32% |
Volatility is currently contracting
Eli Lilly's Olumiant wins FDA nod to treat pediatric patients 12 years of age and older with severe alopecia areata, expanding its U.S. use after strong phase III results.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Citigroup sees a path to 35% gains from here, but Eli Lilly's pricing headwinds, a slow oral GLP-1 launch, and a rival in freefall raise a real question about whether this pause signals opportunity or a longer stall ahead.
Through this commitment, Lilly aims to expand access to its innovative diabetes and obesity medicines to as many people in resource-limited settings, including low- and middle-income countries (LMICs), as in high-income countries, before 2040 Key highlights: Lilly today launched the Lilly Change the Course Commitment , a new global health initiative with a simple, yet ambitious goal: parity in the number of patients treated. This means treating as many people in resource-limited settings, including LMICs 1 , as in high-income countries.
The FDA just handed Eli Lilly a new diabetes approval, but the real debate is whether a once-weekly insulin needle moves the needle on a stock already up 60% and closing in on record highs.
FDA approval supported by data from BRAVE-AA-PEDS, the first and largest Phase 3 study specifically designed to evaluate pediatric patients with severe alopecia areata (AA) Treatment with Olumiant resulted in substantial scalp hair regrowth, as well as improvements in eyebrows and eyelashes Severe AA can result in extensive hair loss during adolescence, a formative stage of life INDIANAPOLIS, Sept. 25, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved Olumiant (baricitinib), a once-daily pill, for the treatment of pediatric patients 12 years of age and older with severe alopecia areata (AA).1 The approval expands Olumiant's U.S. label, building on its established use in adults with moderately to severely active rheumatoid arthritis and severe AA.
Eli Lilly gets FDA approval for once-weekly Onswik, offering adults with type II diabetes a more convenient alternative to daily basal insulin.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The latest rebalance of VettaFi's Thematic Rotation Quality Momentum Screened Index (TQRMS), tracked by the NBI Thematic Rotation ETF (NTHM:TSX), reshapes the portfolio around a new set of themes. GLP-1 weight loss drug manufacturers and midstream energy join the index, while battery technology & storage and software-as-a-service (SaaS) exit.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on LLY and any ticker you trade — then tracks every position and per-strategy win rate.
